These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31152966)

  • 1. Switching for convenience from first-line injectable treatments to oral treatments in multiple sclerosis: Data from a retrospective cohort study.
    Buard G; Giovannelli J; Outteryck O; Hadhoum N; Lannoy J; Vermersch P; Zéphir H
    Mult Scler Relat Disord; 2019 Aug; 33():39-43. PubMed ID: 31152966
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.
    Soini E; Joutseno J; Sumelahti ML
    Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spotlight on teriflunomide.
    Tallantyre E; Evangelou N; Constantinescu CS
    Int MS J; 2008 Jun; 15(2):62-8. PubMed ID: 18782502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A;
    J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Teriflunomide for the treatment of multiple sclerosis.
    Oh J; O'Connor PW
    Semin Neurol; 2013 Feb; 33(1):45-55. PubMed ID: 23709212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Teriflunomide (Aubagio), oral administration].
    J Pharm Belg; 2015 Sep; (3):49-55. PubMed ID: 26513836
    [No Abstract]   [Full Text] [Related]  

  • 8. [TERIFLUNOMIDE: A NEW ORAL IMMUNOMODULATING AGENT FOR MULTIPLE SCLEROSIS].
    Bencsik K; Rózsa C; Vécsei L
    Ideggyogy Sz; 2015 Mar; 68(3-4):79-87. PubMed ID: 26434194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis.
    Miller AE
    Expert Rev Clin Immunol; 2015 Feb; 11(2):181-94. PubMed ID: 25511008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Teriflunomide (Aubagio). New treatment for multiple sclerosis].
    Sabourin G
    Perspect Infirm; 2014; 11(3):56. PubMed ID: 24855766
    [No Abstract]   [Full Text] [Related]  

  • 11. Induction and escalation therapies in multiple sclerosis.
    Fenu G; Lorefice L; Frau F; Coghe GC; Marrosu MG; Cocco E
    Antiinflamm Antiallergy Agents Med Chem; 2015; 14(1):26-34. PubMed ID: 25938688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In process].
    Wagner B
    Med Monatsschr Pharm; 2016 Aug; 39(8):352-3. PubMed ID: 29984957
    [No Abstract]   [Full Text] [Related]  

  • 13. Update on disease-modifying treatments for multiple sclerosis.
    Carrithers MD
    Clin Ther; 2014 Dec; 36(12):1938-1945. PubMed ID: 25218310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
    Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
    Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
    Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatigue Improvement after Switching Multiple Sclerosis Treatment from Interferon-β to Glatiramer Acetate in Clinical Practice.
    Meca-Lallana J; Hernández L; Caminero AB; Girón JM; Cano-Orgaz A; Carcelén-Gadea M; Muñoz D; Durán-Ferreras E; Martín-Hernández J; Sánchez-de la Rosa R;
    Eur Neurol; 2016; 76(1-2):40-7. PubMed ID: 27376845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry.
    Papp V; Buron MD; Siersma V; Rasmussen PV; Illes Z; Kant M; Hilt C; Mezei Z; Roshanisefat H; Sejbæk T; Weglewski A; van Wingerden J; Geertsen SS; Bramow S; Sellebjerg F; Magyari M
    PLoS One; 2021; 16(5):e0250820. PubMed ID: 34003862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany.
    Ziemssen T; Kurzeja A; Muresan B; Haas JS; Alexander J; Driessen MT
    Neurodegener Dis Manag; 2022 Apr; 12(2):93-107. PubMed ID: 34931528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alemtuzumab and teriflunomide approved].
    Fischer S
    Med Monatsschr Pharm; 2013 Oct; 36(10):393-4. PubMed ID: 24266250
    [No Abstract]   [Full Text] [Related]  

  • 20. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.
    Bollo L; Guerra T; Bavaro DF; Monno L; Saracino A; Angarano G; Paolicelli D; Trojano M; Iaffaldano P
    J Neurol Sci; 2020 Sep; 416():117011. PubMed ID: 32650143
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.